Company Overview of OctoPlus N.V.
OctoPlus N.V. operates as a drug delivery and development company worldwide. It offers drug formulation and manufacturing services to pharmaceutical and biotechnology industries; and a platform of proprietary biodegradable polymers for the injectable pharmaceutical products primarily in proteins and peptides. The company’s products include Locteron, which has completed Phase IIb clinical trials for the treatment of chronic hepatitis C; and OP-145 that is in Phase II clinical trials for the treatment of chronic middle ear infection, as well as for the treatment of mucosal infections caused by gram-positive and gram-negative bacteria. It also provides drug delivery technologies, such as OctoDE...
Leiden, 2333 CL
Founded in 1995
Key Executives for OctoPlus N.V.
Chief Executive Officer and Member of Executive Board
Chief Financial Officer and Member of Executive Board
General Manager and Member of Executive Board
Compensation as of Fiscal Year 2014.
OctoPlus N.V. Key Developments
OctoPlus N.V. Presents at BioJapan 2013 World Business Forum, Oct-09-2013
Sep 25 13
OctoPlus N.V. Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.
OctoPlus N.V., Annual General Meeting, Jun 28, 2013
Jun 14 13
OctoPlus N.V., Annual General Meeting, Jun 28, 2013., at 10:00 Central European Standard Time.
OctoPlus N.V.(ENXTAM:OCTO) dropped from Next Biotech Index
Apr 17 13
OctoPlus N.V. will be removed from Next Biotech Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries